Natural history and progression of metabolic dysfunction-associated steatotic liver disease.

Hagström Hannes, Shang Ying, Hegmar Hannes, Nasr Patrik

The lancet. Gastroenterology & hepatology · 2024 · PMID 39243773 · 인용 302

PubMed ↗DOI ↗

The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of patients develop inflammation and risk progressive fibrosis that can result in cirrhosis. Progression to cirrhosis occurs in 3-5% of patients and often takes more than 20 years.

This narrative review presents an update on the natural history of MASLD, discussing studies and risk estimates for progression to severe outcomes, such as decompensated cirrhosis or hepatocellular carcinoma. We highlight the dynamic progression of liver damage, how to identify patients whose disease progresses over time, and how risk factors might be mitigated to reduce the risk for disease progression.

📄 이 논문을 인용한 Paperis 글

이 논문이 근거 목록에 올라 있는 Paperis 글입니다.